Climb Bio, Inc.
CLYM
Get informed when a big investor buys or sells
+ FollowMarket Cap$629.89M
Close$
$0.52
95.2% downside
Current Fair Value
95.2% downsideOvervalued by 95.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $629.89 Million |
|---|---|
| Enterprise Value | $587.10 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.88 |
| Beta | 0.08 |
| Outstanding Shares | 76,154,071 |
Return
| Return on Equity | -24.06% |
|---|---|
| Return on Assets | -23.40% |
| Return on Invested Capital | -27.00% |
Valuation & Multiples
| P/E Ratio | -13.25 |
|---|---|
| PEG | -23.77 |
| Price to Sales | - |
| Price to Book Ratio | 3.64 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -9.05 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Eliem Therapeutics Inc
2,021 employees
CEO: Aoife Brennan BCh MMSc Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This tre...